{"entity":{"id":"nct07069062","kind":"trial","name":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Test product HY0001a for injection in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","summary":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07069062 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 261 participants planned, started 2025-07-21 and due to reach its primary completion in 2027-06. Interventions recorded: Test product HY0001a for injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07069062","url":"https://clinicaltrials.gov/study/NCT07069062"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07069062","phase":"1/2","setting":"A Multicenter, Open-label Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Clinical Efficacy of HY0001a for Injection in Patients With Advanced Malignant Solid Tumors","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","enrolled":261,"outcomes":[]},"route":"/trials/nct07069062/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}